MRI-Guided breast cancer trial aims to spare patients from toxic chemo

NCT ID NCT07327021

Recruiting now Disease control Sponsor: Tel-Aviv Sourasky Medical Center Source: ClinicalTrials.gov ↗

First seen Jan 08, 2026 · Last updated Apr 29, 2026 · Updated 17 times

Summary

This study tests whether an MRI scan can identify triple-negative breast cancer patients who respond well to initial chemotherapy and immunotherapy, allowing them to skip a second, more toxic chemo phase. About 54 participants will receive four cycles of paclitaxel, carboplatin, and pembrolizumab, then get an MRI. Those with a complete response on MRI go straight to surgery, avoiding anthracycline drugs linked to heart problems and leukemia. The goal is to maintain high cure rates while reducing side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TNBC - TRIPLE-NEGATIVE BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Sheba Medical Center
RECRUITING

Tel Litwinsky, Israel

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact
Tel Aviv Sourasky Medical Center
RECRUITING

Tel Aviv, Israel

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact

Conditions

Explore the condition pages connected to this study.

EARLY BREAST CANCER EARLY BREAST CANCER TNBC - TRIPLE-NEGATIVE BREAST CANCER